Genomic ETF Outperformed Following Tech-Driven Gains
The ARK Genomic Revolution ETF returned 86% in 2026, bolstered by substantial surges in its biotech holdings.
Updated on Oct. 5, 2026 in Biotech
Live Poll
Is now a good time to sell high-growth tech stocks to lock in recent gains?
The ARK Genomic Revolution ETF has surged 86% so far in 2026, outperforming other ARK funds. The gains were driven by explosive growth in two major holdings, Twist Bioscience and 10x Genomics, which both saw share values increase nearly sixfold.
Why it matters
The fund's success stems from the increasing intersection of artificial intelligence and biological research. Companies that integrate synthetic DNA services or gene-mapping instruments with AI models are seeing significant market valuation increases.
As of October 2, 2026, Twist Bioscience and 10x Genomics accounted for 20.27% of the ETF. Twist reported third-quarter revenue of $118.4 million with a 52.8% gross margin, while 10x Genomics recently launched the Atera instrument and Sentira platform.
The players
ARK Genomic Revolution ETF
This exchange-traded fund focuses on companies expected to benefit from breakthroughs in genomics and related biotechnologies.
Twist Bioscience
The company specializes in manufacturing synthetic DNA and antibody libraries for customers in the biotechnology and pharmaceutical sectors.
10x Genomics
This life sciences technology firm produces equipment and software used to analyze biological systems at single-cell and tissue-wide resolutions.
The details
Twist Bioscience provides synthetic DNA and antibody-testing services used in AI training, while 10x Genomics manufactures tools for mapping gene activity in tissue. These technical capabilities have fueled investor interest as the firms scale their operational output.
Timeline
Baseline closing prices for the stocks were established at the end of 2025.
Anthropic conducted research involving Twist and Adaptyv Bio in August 2026.
10x Genomics launched Atera shipments and the Sentira platform in September 2026.
ARK disclosed its latest portfolio holdings on October 2, 2026.
10x Genomics expects a paid launch for its Sentira platform in early 2027.
The Tech Race
This performance reflects a structural shift toward biotech companies that provide the foundational infrastructure for AI-driven biological discovery. These firms are replacing older, manual laboratory methods with automated cloud-based analysis platforms and synthetic biology workflows.
For investors, this trend highlights the growing importance of checking the underlying portfolio composition of tech-focused ETFs. Rapidly shifting share prices in biotech can significantly influence fund performance and individual retail investor returns.
The takeaway
The rapid growth of companies like Twist Bioscience and 10x Genomics signals a broader market interest in the practical application of AI within life sciences. Investors should monitor how these firms translate their current technological rollouts into long-term revenue growth.
What happens next
10x Genomics is scheduled to conduct a paid launch of its Sentira analysis platform in early 2027.
Further reading
For more on industry shifts, visit the Biotech section for additional context.
Source note: This article includes information reported by Asianet News Network Pvt Ltd.
Live Poll
Is now a good time to sell high-growth tech stocks to lock in recent gains?
